Impact Factor
3.23
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.75
358 total citations
h5-index
25
h5 depth signal
Cited share
65.9%
91 of 138
Total citations
358
Citation footprint
Metric signal
2.64
External metric anchor
Self-citation
1.4%
5 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Germany
106
United States
78
Japan
78
China
67
Italy
51
Citing Fields of Research
Digestive Disorders
401
Inflammatory Bowel Diseases & Infections
187
Liver Diseases
184
Hepatitis
138
Liver & Colon Cancer
134
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,226
Articles tracked across the journal lifetime
Indexed publication set
138
91 cited publications
Last 12 months
61
5.1 publications/month
Open access share
39.3%
24 OA publications in the last year
Leading citing country
Germany
106 citing publications
Leading citing field
Digestive Disorders
401 citing publications
Latest tracked publication
9 October 2026
10 recent records available
Coverage & Indexing History
v4n1, 1986-
v4n1, 1986-
Active Coverage
Research Focus & Classification
Indexed Subjects
Digestive Disorders
Inflammatory Bowel Diseases & Infections
Hepatitis
Liver Diseases
Broad Categories
Gastroenterology
Digestive Disorders
MeSH Descriptors
Digestive System Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1159/ddi/acnag010
Open DOI
Incidence Trends and Projections of Major Gastrointestinal Cancers in the United States: A SEER-Based Analysis from 2000 to 2022
Background: Gastrointestinal (GI) cancers account for a substantial cancer burden, yet contemporary incidence trends and future projections across cancer sites and demographic subgroups remain incompletely characterized. We aimed to anal...
02
DOI 10.1159/ddi/acnag011
Open DOI
Maintenance of Efficacy Outcomes at Week 52 among Etrasimod Induction Responders: An Analysis from the Phase 3 ELEVATE UC 52 Trial
Introduction: Most trials studying advanced therapies for ulcerative colitis (UC) adopted a responder re‑randomization design. By contrast, a treat-through design was utilized in the ELEVATE UC 52 trial to assess etrasimod, an oral, once...
03
DOI 10.1159/ddi/acnag012
Open DOI
IS PYLERA® STILL EFFECTIVE AND SAFE IN PATIENTS INFECTED BY HELICOBACTER PYLORI? A SIX-YEARS, MULTICENTRE, REAL LIFE STUDY
Introduction: More than ten years after its introduction into clinical practice, we aimed to assess the current real-life effectiveness and safety of bismuth-containing quadruple therapy in patients infected with H. pylori. Methods: Cons...
04
05
DOI 10.1159/ddi/acnag008
Open DOI
Comprehensive analysis of colorectal cancer burden in G20 countries from 1990 to 2023 and projections to 2030: findings from the Global Burden of Disease Study 2023
Introduction: This study aimed to comprehensively assess the CRC burden in G20 countries from 1990 to 2023, analyze temporal trends by age and sex, quantify attributable risk factors, and project future burden to 2030. Methods: Using dat...
06
DOI 10.1159/ddi/acnag006
Open DOI
Sex- and Smoking-Specific Association between Physical Activity and Digestive Cancer Risk
BACKGROUND: This study examined whether suboptimal and excess levels of physical activity (PA) relate to the development of digestive tract cancers, and whether these relationships differ according to sex and smoking history. SUBJECTS/ME...
07
DOI 10.1159/ddi/acnag005
Open DOI
The thirty years trends of gastric cancer attributable to smoking in China and Japan: Demographic decomposition and age-period-cohort analysis
Background: China and Japan showed similar cultural backgrounds and lifestyles. This study aimed to assist China or Japan policymakers in allocating healthcare resources by examining secular trends in gastric cancer (GC) mortality attrib...
08
DOI 10.1159/ddi/acnag004
Open DOI
IL-18/IL-18R1 Involved in Pancreatic Fibrosis via Activating Pancreatic Stellate Cells
Introduction: Chronic pancreatitis (CP) is a fibro-inflammatory syndrome characterized by irreversible tissue damage leading to exocrine and endocrine insufficiency, persistent pain, and an increased risk of pancreatic cancer. This study...
09
DOI 10.1159/ddi/acnag003
Open DOI
Pre-Treatment Histopathological Features Are Associated with Ustekinumab Efficacy in Ulcerative Colitis: A Retrospective Pilot Study
Introduction: Biologic therapy options for ulcerative colitis (UC) have increased in recent years. Although predicting treatment response may support personalized treatment strategies, the predictive value of histopathological features i...
10
DOI 10.1159/ddi/acnag002
Open DOI
Sucralfate/Sodium Alginate Capsules and Proton Pump Inhibitor-Refractory Reflux Symptoms in Nonerosive Reflux Disease and Mild Erosive Disease: A Randomized, Phase 3, Noninferiority Study
Introduction: Proton pump inhibitors have failed to control symptoms in some patients with gastroesophageal reflux disease. We investigated the effect of alginate and sucralfate (ALSUC) capsules in patients who had not responded to proto...
Bibliographical & Catalog Notes
Title from cover.
Also available online.
Vol. 6, no. 1 (1988)19921001 Notice published Printed on acid-free paper